Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb;34(2):405-416.
doi: 10.1007/s11136-024-03821-x. Epub 2024 Oct 29.

Quality of life of inflammatory bowel diseases patients in france with EQ-5D-5 L: the QALY-MICI study

H Sarter  1 , J Kirschgesner  2 , L Beaugerie  2 , A Buisson  3 , C Gower-Rousseau  4 , Gérard de Pouvourville  5
Affiliations

Quality of life of inflammatory bowel diseases patients in france with EQ-5D-5 L: the QALY-MICI study

H Sarter et al. Qual Life Res. 2025 Feb.

Abstract

Purpose: This study aimed to document utility values and the Visual Analog Scale (VAS) with the 5-level version of the EQ-5D questionnaire in a large sample of patients with inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC).

Methods: QALY-MICI was a cross-sectional survey across three sources in France. Data were collected between 2019 and 2022 for patients 18 and over. The EQ-5D-5 L, the EQ-VAS, the Short Inflammatory Bowel Disease Questionnaire (SIBDQ), the Harvey-Bradshaw Index (HBI) for CD, and the Walmsley Index for UC (SCCAI) were collected.

Results: A total of 2,841 patients aged over 18 were recruited (1785 with CD, 1056 with UC). The mean age was 40.2 (SD 14.3). The time since diagnosis was 6 years and over for 61.9% of patients. The most impacted dimensions were usual activities, anxiety/ depression, and pain/ discomfort. The mean utility value was 0.863 (SD 0.172) versus 0.905 (SD 0.158) in the French population (p = 0.007). The mean VAS value was 68 (SD 19.2) versus 73.4 (SD 22.2) in the general population (p = 0.016). Utility values and VAS were similar for CD and UC and higher for men. There was a strong positive correlation between utility values, the VAS, and the SIBDQ score, and a negative correlation between the HBI and the SCCAI. The SIBDQ score and disease activity were the main predictors of utility and VAS.

Conclusion: The QALY-MICI is, to our knowledge, the first study documenting utility values and VAS using the EQ-5D-5 L questionnaire on a large sample, with a comparison to the general population.

Keywords: EQ-5D-5L; France; Inflammatory bowel disease; Utility values.

Plain language summary

Cost-effectiveness analyses have become an important component of assessing new health technologies. They require robust evidence to measure Quality of Life Adjusted Life Year gains. The Euroqol EQ-5D questionnaire is the main standard.Data on its use in inflammatory bowel disease (IBD) with its latest version, EQ-5D-5L, are limited to small samples.This study aimed at estimating utility values for IBD patients on a large sample in France, analysing the relationship between specific IBD quality of life and disease activity indexes, and identifying the main factors impacting patients’ quality of life.A prospective, cross-sectional survey was designed amongst French IBD patients aged 18 and over from three sources (n=2,841) . Utility values for IBD patients were lower than those observed in the French general population across all age groups. Men declared higher values than women. There was no difference between patients with Crohn’s disease and those with ulcerative colitis. Patients with a quiescent disease had similar values to those of the general population.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval: This study has received a registration of compliance to MR3 reference methodology (n° 2200570 v 0). Research methodology MR3 does not require informed consent to participate, since the research was not interventional. But all respondents were given a letter of information on their rights to access to their personal data and to retrieve them. It has received an approval form the Personal Protection Committee (CPP) on November 20, 2018, under the registration number ID-RCB 2018-A02189-46. The study is registered at the National Drugs Agency (ANSM) under the preceding number. Informed consent: See preceding statement. Conflict of interest: Funding was made to institutions. None of the authors received personal funding for the research.

References

    1. Alrubaiy, L., Rikaby, I., Dodds, P., Hutchings, H. A., & Williams, J. G. (2015). Systematic review of health-related quality of life measures for inflammatory bowel disease. J Crohns Colitis, 9(3), 284–292. https://doi.org/10.1093/ecco-jcc/jjv002 Epub 2015 Jan 9. - DOI
    1. Armuzzi, A., Tarallo, M., Lucas, J., Bluff, D., Hoskin, B., Bargo, D., Cappelleri, J. C., Salese, L., & daCosta DiBonaventura, M. (2020). The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe. Bmc Gastroenterology, 20(1), 18. https://doi.org/10.1186/s12876-020-1164-0 - DOI - PMC
    1. Benedini V., Caporaso N., Corazza GR., Rossi Z., Fornaciari G., Cottone M., Frosini G., Caruggi M., Ottolini C., Colombo G.L.Burden of Crohn’s disease: economics and quality of life aspects in Italy. Clinicoecon Outcomes Res. 2012;4:209-18. doi: 10.2147/CEOR.S31114.
    1. Gibson, P. R., Vaizey, C., Black, C. M., Nicholls, R., Weston, A. R., Bampton, P., Sparrow, M., Lawrance, I. C., Selby, W. S., Andrews, J. M., Walsh, A. J., Hetzel, D. J., Macrae, F. A., Moore, G. T., Weltman, M. D., Leong, R. W., & Fan, T. (2014). Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: A cross-sectional, observational study. J Crohns Colitis, 8(7), 598–606. https://doi.org/10.1016/j.crohns.2013.11.017 - DOI
    1. Knowles, S. R., Graff, L. A., Wilding, H., Hewitt, C., Keefer, L., & Mikocka-Walus, A. (2018). Quality of life in inflammatory bowel disease: A systematic review and Meta-analyses-part I. Inflammatory Bowel Diseases, 24(4), 742–751. https://doi.org/10.1093/ibd/izx100 - DOI

LinkOut - more resources